Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
GBT

Global Blood Therapeutics

$42.53

-3.525 (-7.65%)

08:49
09/14/18
09/14
08:49
09/14/18
08:49
Recommendations
Global Blood Therapeutics analyst commentary at William Blair »

William Blair sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

GBT

Global Blood Therapeutics

$42.53

-3.525 (-7.65%)

07:52
09/14/18
09/14
07:52
09/14/18
07:52
Recommendations
Global Blood Therapeutics analyst commentary at Nomura Instinet »

Global Blood shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

GBT

Global Blood Therapeutics

$41.70

-4.35 (-9.45%)

, SRPT

Sarepta

$151.69

1.04 (0.69%)

11:41
09/13/18
09/13
11:41
09/13/18
11:41
Recommendations
Global Blood Therapeutics, Sarepta analyst commentary at H.C. Wainwright »

H.C. Wainwright remains…

GBT

Global Blood Therapeutics

$41.70

-4.35 (-9.45%)

SRPT

Sarepta

$151.69

1.04 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

GBT

Global Blood Therapeutics

$41.80

-4.25 (-9.23%)

11:39
09/13/18
09/13
11:39
09/13/18
11:39
Periodicals
Global Blood's FDA filing strategy for sickle cell 'risky,' STATNews says »

Global Blood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

BLUE

Bluebird Bio

$148.25

-4.85 (-3.17%)

, BOLD

Audentes Therapeutics

$35.57

1.13 (3.28%)

15:55
09/12/18
09/12
15:55
09/12/18
15:55
Conference/Events
William Blair biotech analyst to hold a group event »

Biotech Analyst Prasad…

BLUE

Bluebird Bio

$148.25

-4.85 (-3.17%)

BOLD

Audentes Therapeutics

$35.57

1.13 (3.28%)

GBT

Global Blood Therapeutics

$45.80

-0.65 (-1.40%)

KRYS

Krystal Biotech

$18.54

-2.58 (-12.22%)

LOXO

Loxo Oncology

$165.27

-5.27 (-3.09%)

PTCT

PTC Therapeutics

$47.09

-0.31 (-0.65%)

RCKT

Rocket Pharmaceuticals

$24.03

-0.54 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 23

    Sep

  • 26

    Nov

  • 01

    Dec

BLUE

Bluebird Bio

$153.10

4.3 (2.89%)

, BOLD

Audentes Therapeutics

$34.44

-1.27 (-3.56%)

04:55
09/12/18
09/12
04:55
09/12/18
04:55
Conference/Events
William Blair biotech analyst to hold a group event »

Biotech Analyst Prasad…

BLUE

Bluebird Bio

$153.10

4.3 (2.89%)

BOLD

Audentes Therapeutics

$34.44

-1.27 (-3.56%)

GBT

Global Blood Therapeutics

$46.45

0.85 (1.86%)

KRYS

Krystal Biotech

$21.12

1.62 (8.31%)

LOXO

Loxo Oncology

$170.54

5.19 (3.14%)

PTCT

PTC Therapeutics

$47.40

0.39 (0.83%)

RCKT

Rocket Pharmaceuticals

$24.57

0.07 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 23

    Sep

  • 26

    Nov

  • 01

    Dec

BLUE

Bluebird Bio

$150.60

-1.55 (-1.02%)

, BOLD

Audentes Therapeutics

$33.91

-3.23 (-8.70%)

15:34
09/07/18
09/07
15:34
09/07/18
15:34
Conference/Events
William Blair biotech analyst to hold a group event »

Biotech Analyst Prasad…

BLUE

Bluebird Bio

$150.60

-1.55 (-1.02%)

BOLD

Audentes Therapeutics

$33.91

-3.23 (-8.70%)

GBT

Global Blood Therapeutics

$44.85

-0.5 (-1.10%)

KRYS

Krystal Biotech

$18.47

1.17 (6.76%)

LOXO

Loxo Oncology

$160.74

-0.88 (-0.54%)

PTCT

PTC Therapeutics

$45.91

2.02 (4.60%)

RCKT

Rocket Pharmaceuticals

$23.41

0.17 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 23

    Sep

  • 26

    Nov

  • 01

    Dec

Over a month ago
GBT

Global Blood Therapeutics

$49.80

-1.25 (-2.45%)

13:08
08/23/18
08/23
13:08
08/23/18
13:08
Recommendations
Global Blood Therapeutics analyst commentary at Piper Jaffray »

Global Blood expands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 12

    Sep

GBT

Global Blood Therapeutics

$51.05

1.55 (3.13%)

08:10
08/23/18
08/23
08:10
08/23/18
08:10
Hot Stocks
Global Blood Therapeutics enters licensing agreement with Roche for inclacumab »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

DBX

Dropbox

$28.23

-0.71 (-2.45%)

, SCHW

Charles Schwab

$51.14

0.9 (1.79%)

08:45
08/17/18
08/17
08:45
08/17/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

DBX

Dropbox

$28.23

-0.71 (-2.45%)

SCHW

Charles Schwab

$51.14

0.9 (1.79%)

BHP

BHP Billiton

$47.25

0.29 (0.62%)

HEAR

Turtle Beach

$26.24

1.07 (4.25%)

RAD

Rite Aid

$1.41

0.05 (3.69%)

CVRR

CVR Refining

$18.25

0.05 (0.27%)

GBT

Global Blood Therapeutics

$49.95

2.1 (4.39%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$43.12

2.96 (7.37%)

MNKD

MannKind

$1.13

0.01 (0.90%)

GALT

Galectin Therapeutics

$3.85

0.165 (4.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.